Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
AssigneeSt. Jude Children's Research Hospital
InventorsIda Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
Life of this patent
Estimating the term…
Loading patent…
AssigneeSt. Jude Children's Research Hospital
InventorsIda Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
Estimating the term…
Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile. As such, the level of lysosomal exocytosis activity and/or lysosomal sialidase activity is predictive of a diagnosis and/or prognosis of cancer, chemotherapy resistance or dementia associated with Alzheimer's disease.
A method of determining the prognosis for a subject with cancer, comprising the steps of
A method of diagnosing cancer in a subject, the method comprising:
A method of determining the prognosis for a lysosomotropic chemotherapeutic agent regime in a subject with cancer, comprising the steps of
-11. (canceled)
A method of diagnosing dementia associated with Alzheimer's disease in a subject, the method comprising:
-26. (canceled)
A method of treating a subject with dementia associated with Alzheimer's disease or treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of Neuramimidase 1 (NEU1) polypeptide having an amino acid sequence with at least 85% sequence identity to SEQ ID NO:
A method of generating a lysosomal sialidase activity profile comprising:
A method of generating a lysosomal exocytosis activity profile from cerebrospinal fluid comprising:
(canceled)
(canceled)
Dependencies are inferred from the claim text.